Protective outcomes of high-affinity monoclonal antibodies against drug-resistant plague strains - Takeaways - MDSpire

Protective outcomes of high-affinity monoclonal antibodies against drug-resistant plague strains

  • By

  • Wenxuan Peng

  • Hailian Wu

  • Li Zhang

  • Binyang Zheng

  • Qi Zhang

  • Wenyuan Xin

  • Xiaoyan Yang

  • Kaiye Ying

  • Ru Ma

  • Hongxing Pan

  • Qingwen Zhang

  • Haisheng Wu

  • June 23, 2026

  • 0 min

Share

  • 1

    Yersinia pestis causes plague and has developed streptomycin-resistant strains, necessitating new therapeutic strategies.

  • 2

    Monoclonal antibodies Fm3 and Fm25 were generated from mice immunized with Y. pestis vaccine strain EV76.

  • 3

    Fm3 and Fm25 provided 100% protection against Y. pestis strain 141 at 100 µg dosage in mice.

  • 4

    Fm25 achieved total survival against drug-resistant Y. pestis strain S19960127 at 100 µg, while Fm3 offered 75% protection.

  • 5

    Neither Fm3 nor Fm25 showed protective efficacy at lower dosages of 20 µg or 4 µg against both Y. pestis strains.

Original Source(s)

Protective outcomes of high-affinity monoclonal antibodies against drug-resistant plague strains

  • by Wenxuan Peng, Hailian Wu, Li Zhang, Binyang Zheng, Qi Zhang, Wenyuan Xin, Xiaoyan Yang, Kaiye Ying, Ru Ma, Hongxing Pan, Qingwen Zhang, Haisheng Wu

  • June 23, 2026

Related Content

Engagement Trends in Online Vaccine Content: Longitudinal YouTube Study

Self-administered digital vaccination decision-aids in primary care: A pilot study of COVID-19 vaccination in Atlanta, GA

Ebola at the World Cup? Here’s what we should actually worry about